GAVI negotiates HPV vaccine prices for developing countries

 
• By Francesca Bruce
  
Generate a summary of this article
Listen to this article
Beta

The GAVI Alliance has announced it is to fund vaccines against the human papillomavirus (HPV) and negotiations with the companies that market vaccines, GlaxoSmithKline and Merck & Co, are underway, said a GAVI spokesperson. The public-private vaccination initiative says it must secure a "sustainable price" from manufacturers. It is unclear what this price might be, but will likely be below $5 per dose.

The GAVI Alliance has announced it is to fund vaccines against the human papillomavirus (HPV) and negotiations with the companies that market vaccines, GlaxoSmithKline and Merck & Co, are underway, said a GAVI spokesperson. The public-private vaccination initiative says it must secure a "sustainable price" from manufacturers. It is unclear what this price might be, but will likely be below $5 per dose.

GSK and Merck & Co market Cervarix and Gardasil respectively. UNICEF, GAVI's procurement partner, says it will only buy vaccines...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anti-infective

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed

PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.

Bavarian Nordic Well Placed To Meet Mpox Vaccine Demand

 
• By Andrew McConaghie

The company will ramp up manufacturing of its Jynneos vaccine to meet demand in worst-affected African countries and stockpiling richer nations.  

Cagrisema Leads The Charge For 2025

 
• By Elizabeth Cairns

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.